Y Intercept Hong Kong Ltd Takes Position in Pyxis Oncology, Inc. $PYXS

Y Intercept Hong Kong Ltd purchased a new position in Pyxis Oncology, Inc. (NASDAQ:PYXS) during the second quarter, Holdings Channel.com reports. The fund purchased 133,047 shares of the company’s stock, valued at approximately $146,000.

A number of other hedge funds also recently modified their holdings of the stock. Bank of America Corp DE lifted its stake in Pyxis Oncology by 20.3% in the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after purchasing an additional 9,062 shares during the last quarter. Pier 88 Investment Partners LLC raised its stake in shares of Pyxis Oncology by 296.6% in the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company’s stock valued at $383,000 after buying an additional 292,370 shares during the period. Nuveen LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $125,000. 683 Capital Management LLC lifted its position in shares of Pyxis Oncology by 32.5% during the 1st quarter. 683 Capital Management LLC now owns 550,000 shares of the company’s stock valued at $539,000 after buying an additional 135,000 shares during the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology during the 1st quarter worth $81,000. Institutional investors own 39.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on PYXS shares. Zacks Research cut Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Wednesday, October 8th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Monday, November 3rd. They issued a “buy” rating and a $9.00 price objective for the company. Finally, Guggenheim boosted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $7.25.

Pyxis Oncology Trading Down 3.2%

PYXS stock opened at $3.91 on Monday. The firm has a 50 day moving average of $2.73 and a 200-day moving average of $1.73. Pyxis Oncology, Inc. has a 12 month low of $0.83 and a 12 month high of $5.39. The firm has a market capitalization of $243.44 million, a P/E ratio of -2.44 and a beta of 1.40.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. Sell-side analysts predict that Pyxis Oncology, Inc. will post -1.04 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.